Search results - 9 results
Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening?
a low risk of CIN3 + after a negative APTIMA test over a longer period is awaited to inform us about its utility in cervical cancer screening at 5-year or longer intervals Health Topics: Cancer Cancer ...
Are 20 human papillomavirus types causing cervical cancer?
(HPV16, HPV31, HPV33, HPV35, HPV52, HPV58). Less evidence is available for a thirteenth type (HPV68, α7), which is classified as a 2A carcinogen (probably carcinogenic). Moreover, seven other ...
Clinical evaluation of a GP5+/6+-based luminex assay having full high-risk human papillomavirus genotyping capability and an internal control.
Oligonucleotide Probes Papillomaviridae Papillomavirus Infections Reference Standards Sensitivity and Specificity Young adult Abstract: The LMNX genotyping kit HPV GP (LMNX) is based on the clinically validated GP5 ...
Thyroid cancer incidence in the vicinity of nuclear sites in Belgium 2000-2008
https://www.sciensano.be/en/biblio/thyroid-cancer-incidence-vicinity-nuclear-sites-belgium-2000-2008
environment evidence exposure Hand health Health outcome incidence Increase Increases Iodine IS Isotopes Leukemia living nuclear site observed ON outcome plant Plants POISSON Poisson regression POPULATION ...
Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
Keywords: clinical efficacy immunogenicity prophylactic HPV vaccines Abstract: This is the protocol for a review and there is no abstract. The objectives are as follows: To evaluate the immunogenicity, ...
Cytological screening for cervical cancer in the province of Limburg, Belgium.
Abstract: Cervical cancer screening in Belgium is mainly opportunistic with periodic attempts to organize it according to the European guidelines. In the province of Limburg (north-east Belgium), a cervical ...
Introduction of human papillomavirus (HPV) vaccination in Belgium, 2007-2008.
of human papillomavirus (HPV) vaccine introduction in Belgium. Information on vaccine use is based on sales statistics and reimbursement claims. From November 2007 to November 2008, the National ...
Screening for cervical cancer in Belgium" in Description of the national situation of cervical cancer screening in the member states of the European Union
European Union. There is yet high diversity in the status of cervical screening, and rapid changes expected to occur in the situation in many countries. It is important to underline differences in the health ...
The challenges of organising cervical screening programmes in the 15 old member states of the European Union.
cancer in some, but not all, of the other old member states (belonging to the European Union since 1995) but at a cost that is several times greater. Well organised screening programmes have the potential ...